Today: 7 February 2026
Subscribe
Browse Category

NYSE:ABBV News 15 January 2026 - 25 January 2026

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie shares rose 0.5% to $219.26 Friday, shrugging off India’s rejection of its patent application for the cancer drug venetoclax. The Indian patent office cited lack of novelty and opposition from seven parties. AbbVie will report Q4 and full-year earnings on Feb. 4. Investors remain focused on patent risks and upcoming guidance as the company adjusts after Humira’s decline.
25 January 2026
····
AbbVie stock price: ABBV ends higher into weekend, with India patent setback and Feb. 4 earnings in focus

AbbVie stock price: ABBV ends higher into weekend, with India patent setback and Feb. 4 earnings in focus

New York, Jan 24, 2026, 10:54 EST — Market closed. AbbVie shares closed Friday 0.53% higher at $219.26, securing a slightly stronger position ahead of the weekend shutdown of U.S. markets. (https://finance.yahoo.com/quote/ABBV/history/) That modest shift carries weight as the stock approaches the final stretch before AbbVie’s upcoming earnings report, where guidance and pipeline news often set the tone for what comes next. With the next U.S. session on Monday, traders will be watching closely to see if new developments overseas shake market sentiment. AbbVie is also caught in a market that’s grown wary again, driving some investors to favor large,
24 January 2026
····
AbbVie stock rises as India rejects Venetoclax patent bid; ABBV traders eye Feb. 4 earnings

AbbVie stock rises as India rejects Venetoclax patent bid; ABBV traders eye Feb. 4 earnings

New York, Jan 23, 2026, 15:06 EST — Regular session AbbVie Inc. shares rose about 0.6% on Friday after an Indian report said the country’s patent office rejected the drugmaker’s bid to patent venetoclax, a blood-cancer treatment sold as Venclexta. The stock was up 0.6% at $219.33 in afternoon trade, even as the Health Care Select Sector SPDR Fund fell about 0.6%. The patent call matters because exclusivity is what keeps branded cancer drugs priced well above copycats. When that protection weakens, investors start rerunning the long-term sales math, even if the immediate hit looks small. India is a hard
23 January 2026
····
AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week

New York, Jan 22, 2026, 8:47 PM EST — Market closed. AbbVie Inc (ABBV.N) shares climbed 0.9% Thursday, finishing at $218.11. The stock traded in a range from $214.81 to $219.04, with roughly 5.7 million shares exchanged. U.S. markets remain closed until Friday, leaving AbbVie’s next move more likely driven by pre-market developments — rate forecasts, policy news, and the kickoff of a busy earnings season — than by Thursday’s close. AbbVie’s Feb. 4 earnings report carries weight as investors want more than just past numbers—they’re after clear signals on demand and pricing for 2026. Thursday’s trading looked like a
23 January 2026
·····
AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

New York, January 21, 2026, 18:56 EST — After-hours AbbVie Inc. shares climbed 0.99% to $216.15 Wednesday, fluctuating between $211.57 and $218.00 during the session. After-hours trading saw little movement. Around 10.7 million shares exchanged hands, matching the drugmaker’s typical volume. (StockAnalysis) The timing is crucial as AbbVie approaches its full-year and fourth-quarter earnings report in two weeks. So far, the stock has been priced more on its 2026 outlook than any recent news. Investors are eager for confirmation that the company’s newer growth engines can sustain momentum amid rising pressure on its older products. Wall Street’s attention to “neutral”
22 January 2026
·····
AbbVie stock edges higher as Berenberg lifts target; tariffs and Feb. 4 earnings in play

AbbVie stock edges higher as Berenberg lifts target; tariffs and Feb. 4 earnings in play

New York, January 21, 2026, 12:40 EST — Regular session AbbVie Inc shares were up 88 cents, or about 0.4%, at $214.92 in midday trading on Wednesday, a muted move after a fresh round of analyst target changes. The stock has traded between $211.92 and $218.00, with about 5.3 million shares changing hands. It matters now because drugmakers are heading into results season with policy risk back in the tape. AbbVie’s setup is familiar: investors want proof that newer brands can keep carrying growth while the company navigates tighter pricing. Washington is also back in the conversation. The Trump administration
21 January 2026
····
AbbVie stock slips as traders watch Epkinly data and the next earnings clock

AbbVie stock slips as traders watch Epkinly data and the next earnings clock

New York, January 20, 2026, 13:13 ET — Regular session underway Shares of AbbVie Inc slipped 82 cents, or 0.4%, to $213.53 in early afternoon trading on Tuesday, fluctuating between $210.00 and $214.23. Around 2.9 million shares changed hands. The tick-by-tick move was modest, yet AbbVie’s shares have grown quick to respond to drug data. Investors are grappling with the impact of new oncology assets as the company shifts more aggressively toward newer brands to offset Humira-era revenue declines. The pressure plays out in what grabs focus: clinical endpoints, regulatory routes, and upcoming guidance updates. A typical down day can
20 January 2026
·····
AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs

AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs

New York, January 19, 2026, 11:19 EST — Market closed. AbbVie Inc shares ended Friday at $214.35, slipping $2.44, or roughly 1.1%. This drop came after AbbVie and partner Genmab announced their blood cancer drug epcoritamab did not demonstrate a clear overall-survival benefit in a late-stage trial. (Reuters) U.S. markets were closed Monday for Martin Luther King Jr. Day, giving investors extra time to process the latest readout ahead of the next session. That break is significant since traders often respond sharply to trial conclusions when the upcoming trigger is an earnings report rather than fresh economic data. (MarketWatch) Epcoritamab
19 January 2026
······
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

New York, Jan 18, 2026, 11:03 EST — Market closed AbbVie’s stock dropped on Friday after partner Genmab announced that a late-stage trial of epcoritamab failed to meet its primary endpoint of improving overall survival in blood cancer patients. AbbVie closed at $214.35, down 1.1%. Genmab’s U.S.-listed shares tumbled over 7%. The companies said they still expect data from two other late-stage epcoritamab trials in 2026, including studies combining the drug with standard chemotherapy and Bristol Myers Squibb’s Revlimid. (Reuters) Why this matters now: AbbVie is hunting for fresh growth drivers as investors question the staying power of its lineup
18 January 2026
·······
AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next

AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next

New York, Jan 16, 2026, 20:14 EST — Market closed AbbVie shares slipped 1.1% to close at $214.35 on Friday following mixed late-stage results for its lymphoma treatment, epcoritamab. In after-hours trading, the stock was last seen near $214.66, as U.S. indexes showed little movement. (Investing.com) The readout arrives at a tough time for bulls. AbbVie is hustling to keep its growth story alive amid growing investor scrutiny of its oncology pipeline, with epcoritamab standing out as a key focus. Reuters reported that the Phase 3 trial missed its main goal, failing to deliver a statistically significant boost in overall
17 January 2026
·····
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

New York, Jan 16, 2026, 14:14 ET — Regular session AbbVie Inc shares dropped 1.1% to $214.35 Friday afternoon after releasing mixed results from a late-stage trial of its lymphoma drug epcoritamab. The Phase 3 study hit its primary endpoint, showing improved progression-free survival — meaning patients lived longer without their cancer worsening — but it missed a statistically significant gain in overall survival, the company said. AbbVie and partner Genmab said they plan to consult regulators on the next steps. (AbbVie News Center) The readout arrives at a sensitive moment for AbbVie stock. Investors are closely tracking how the
16 January 2026
·····
AbbVie stock slides 2% as obesity push takes center stage at JPM conference

AbbVie stock slides 2% as obesity push takes center stage at JPM conference

New York, January 15, 2026, 12:11 (EST) — Regular session AbbVie shares dropped 2.1% to $217.13 Thursday following the company’s expanded plans for obesity treatments announced at the J.P. Morgan Healthcare Conference. This matters since AbbVie is hunting for its next major growth driver, as its aging blockbuster Humira grapples with increased competition from biosimilars. Investors have shown they’re eager to back solid obesity treatments—and just as ready to slam unclear prospects. Obesity drugs are turning into a fresh battleground for big pharma. Novo Nordisk and Eli Lilly currently lead the pack, but future victors may hinge on side effects,
15 January 2026
···
1 2 3 4 … 7

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop